RecruitingPhase 1Phase 2NCT06739226

Combination Immunotherapy Targeting Melanoma

Combination of CARTs, CTLs and DC Vaccines Targeting Melanoma

Sponsor

Shenzhen Geno-Immune Medical Institute

Enrollment

30 participants

Start Date

Aug 31, 2025

Study Type

INTERVENTIONAL

Conditions

Melanoma

Summary

The purpose of this study is to assess the feasibility, safety and efficacy of combination immunotherapy based on CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines modified with GM-CSF and B7-2 (CD86) against melanoma, which targets CAR T specific surface antigens such as GD2, CTL specific antigens such as MAGE-A4, gp100 and a pool of melanoma specific antigens presented by the DCs. Another goal of the study is to learn more about the function and persistence of the CAR T cells and antigen-specific immune effectors in patients.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests a combination immunotherapy approach for advanced melanoma (skin cancer) in patients whose disease progressed after standard first-line treatment. The therapy targets proteins specific to melanoma cells using the immune system. **You may be eligible if...** - You have been diagnosed with non-removable, metastatic, or recurring melanoma - You have already received standard first-line therapy - Your tumor has been confirmed to express melanoma-specific proteins by lab testing - You weigh at least 40 kg and are between 18 and 75 years old - You have a life expectancy of at least 8 weeks **You may NOT be eligible if...** - You have not previously tried standard melanoma therapy - Your tumor does not express the required melanoma proteins - Your overall health or organ function does not meet study requirements Talk to your doctor to see if this trial is right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Print for Your Doctor Check Your Eligibility